Lipopolysaccharide regulated protein expression is only partly impaired in monocytes from patients with type I diabetes

Cardiovascular Diabetology

Volumn 5, Issue , 2006, Pages

  Wehrwein, Gabriele ^a   Neumeier, Markus ^a   Schäffler, Andreas ^a   Kopp, Andrea ^a   Weigert, Johanna ^a   Abke, Sabine ^a   Schölmerich, Jürgen ^a   Buechler, Christa ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; INSULIN; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MANGANESE SUPEROXIDE DISMUTASE; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CELL ACTIVATION; CELL CULTURE; CELL ISOLATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INFLAMMATION; INNATE IMMUNITY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MONOCYTE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; QUANTITATIVE ANALYSIS; RANK SUM TEST; VASCULAR DISEASE;

ADULT; APOLIPOPROTEINS E; BLOOD PROTEINS; CASE-CONTROL STUDIES; CELLS, CULTURED; CHEMOKINE CCL2; CHEMOKINES, CXC; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MIDDLE AGED; MONOCYTES; SUPEROXIDE DISMUTASE;

EID: 33746596990     PISSN: 14752840     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-5-5     Document Type: Article

References (40)

1. Campbell IL, Kay TW, Oxbrow L, Harrison LC: Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. J Clin Invest 1991, 87:739-742.
2. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15:539-553.
3. Jensen T, Deckert T: Diabetic retinopathy, nephropathy and neuropathy. Generalized vascular damage in insulin-dependent diabetic patients. Horm Metab Res Suppl 1992, 26:68-70.
4. Singer DE, Nathan DM, Anderson KM, Wilson PW, Evans JC: Association of HbAlc with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 1992, 41:202-208.
5. Patterson JE, Andriole VT: Bacterial urinary tract infections in diabetes. Infect Dis Clin North Am 1997, 11:735-750.
6. Geerlings SE, Hoepelman AI: Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol 1999, 26:259-265.
7. Spatz M, Eibl N, Hink S, Wolf HM, Fischer GF, Mayr WR, Schernthaner G, Eibl MM: Impaired primary immune response in type-1 diabetes. Functional impairment at the level of APCs and T-cells. Cell Immunol 2003, 221:15-26.
8. Ohno Y, Aoki N, Nishimura A: In vitro production of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab 1993, 77:1072-1077.
9. Geerlings SE, Brouwer EC, Van Kessel KC, Gaastra W, Stolk RP, Hoepelman AI: Cytokine secretion is impaired in women with diabetes mellitus. Eur J Clin Invest 2000, 30:995-1001.
10. Alleva DG, Pavlovich RP, Grant C, Kaser SB, Beller DI: Aberrant macrophage cytokine production is a conserved feature among autoimmune-prone mouse strains: elevated interleukin (IL)-12 and an imbalance in tumor necrosis factor-alpha and IL-10 define a unique cytokine profile in macrophages from young nonobese diabetic mice. Diabetes 2000, 49:1106-1115.
11. Bouma G, Nikolic T, Coppens JM, van Helden-Meeuwsen CG, Leenen PJ, Drexhage HA, Sozzani S, Versnel MA: NOD mice have a severely impaired ability to recruit leukocytes into sites of inflammation. Eur J Immunol 2005, 35:225-235.
12. Hashimoto S, Morohoshi K, Suzuki T, Matsushima K: Lipopolysaccharide-inducible gene expression profile in human monocytes. Scand J Infect Dis 2003, 35:619-627.
13. Bouma G, Coppens JM, Lam-Tse WK, Luini W, Sintnicolaas K, Levering WH, Sozzani S, Drexhage HA, Versnel MA: An increased MRP8/14 expression and adhesion, but a decreased migration towards proinflammatory chemokines of type 1 diabetes monocytes. Clin Exp Immunol 2005, 141:509-517.
14. Charo IF, Ransohoff RM: The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006, 354:610-621.
15. Tian L, White JE, Lin HY, Haran VS, Sacco J, Chikkappa G, Davis FB, Davis PJ, Tsan MF: Induction of Mn SOD in human monocytes without inflammatory cytokine production by a mutant endotoxin. Am J Physiol 1998, 275:C740-7.
16. Pociot F, Lorenzen T, Nerup J: A manganese superoxide dismutase (SOD2) gene polymorphism in insulin-dependent diabetes mellitus. Dis Markers 1993, 11:267-274.
17. Karima M, Kantarci A, Ohira T, Hasturk H, Jones VL, Nam BH, Malabanan A, Trackman PC, Badwey JA, Van Dyke TE: Enhanced superoxide release and elevated protein kinase C activity in neutrophils from diabetic patients: association with periodontitis. J Leukoc Biol 2005, 78:862-870.
18. Ali K, Middleton M, Pure E, Rader DJ: Apolipoprotein E suppresses the type 1 inflammatory response in vivo. Circ Res 2005, 97:922-927.
19. Larkin L, Khachigian LM, Jessup W: Regulation of apolipoprotein E production in macrophages (review). Int J Mol Med 2000, 6:253-258.
20. Zuckerman SH, O'Neal L: Endotoxin and GM-CSF-mediated down-regulation of macrophage apo E secretion is inhibited by a TNF-specific monoclonal antibody. J Leukoc Biol 1994, 55:743-748.
21. Lehr HA, Sagban TA, Ihling C, Zahringer U, Hungerer KD, Blumrich M, Reifenberg K, Bhakdi S: Immunopathogenesis of atherosclerosis: endotoxin accelerates atherosclerosis in rabbits on hypercholesterolemic diet. Circulation 2001, 104:914-920.
22. Wiedermann CJ, Kiechl S, Dunzendorfer S, Schratzberger P, Egger G, Oberhollenzer F, Willeit J: Association of endotoxemia with carotid atherosclerosis and cardiovascular disease: prospective results from the Bruneck Study. J Am Coll Cardiol 1999, 34:1975-1981.
23. Bjorkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, Means T, Halmen K, Luster AD, Golenbock DT, Freeman MW: Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med 2004, 10:416-421.
24. Ishida BY, Blanche PJ, Nichols AV, Yashar M, Paigen B: Effects of atherogenic diet consumption on lipoproteins in mouse strains C57BL/6 and C3H. J Lipid Res 1991, 32:559-568.
25. Lobbes MB, Lutgens E, Heeneman S, Cleutjens KB, Kooi ME, van Engelshoven JM, Daemen MJ, Nelemans PJ: Is there more than C-reactive protein and fibrinogen? The prognostic value of soluble CD40 ligand, interleukin-6 and oxidized low-density lipoprotein with respect to coronary and cerebral vascular disease. Atherosclerosis 2005.
26. Charo IF, Taubman MB: Chemokines in the pathogenesis of vascular disease. Circ Res 2004, 95:858-866.
27. Grainger DJ, Reckless J, McKilligin E: Apolipoprotein E modulates clearance of apoptotic bodies in vitro and in vivo, resulting in a systemic proinflammatory state in apolipoprotein E-deficient mice. J Immunol 2004, 173:6366-6375.
28. Inoue M, Sato EF, Nishikawa M, Park AM, Kira Y, Imada I, Utsumi K: Mitochondrial generation of reactive oxygen species and its role in aerobic life. Curr Med Chem 2003, 10:2495-2505.
29. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH: Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000, 101:1767-1772.
30. Koukkunen H, Penttila K, Kemppainen A, Halinen M, Penttila I, Rantanen T, Pyorala K: C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris. Ann Med 2001, 33:37-47.
31. Liberatore Rdel RJ, Barbosa SF, Alkimin MG, Bellinati-Pires R, Florido MP, Isaac L, Kirschfink M, Grumach AS: Is immunity in diabetic patients influencing the susceptibility to infections? Immunoglobulins, complement and phagocytic function in children and adolescents with type 1 diabetes mellitus. Pediatr Diabetes 2005, 6:206-212.
32. Rollins BJ, Yoshimura T, Leonard EJ, Pober JS: Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-1/JE. Am J Pathol 1990 136:1229-1233.
33. Ferreira AM, Rollins BJ, Faunce DE, Burns AL, Zhu X, Dipietro, LA: The effect of MCP-1 depletion on chemokine and chemokine-related gene expression: evidence for a complex network in acute inflammation. Cytokine 2005, 30:64-71.
34. Puddu GM, Cravero E, Arnone G, Muscari A, Puddu P: Molecular aspects of atherogenesis: new insights and unsolved questions. J Biomed Sci 2005, 12:839-853.
35. Ndengele MM, Muscoli C, Wang ZQ, Doyle TM, Matuschak GM, Salvemini D: Superoxide potentiates NF-kappaB activation and modulates endotoxin-induced cytokine production in alveolar macrophages. Shock 2005, 23:186-193.
36. Werb Z, Chin JR: Endotoxin suppresses expression of apoprotein E by mouse macrophages in vivo and in culture. A biochemical and genetic study. J Biol Chem 1983, 258:10642-10648.
37. Guha M, Mackman N: LPS induction of gene expression in human monocytes. Cell Signal 2001, 13:85-94.
38. Scherle PA, Jones EA, Favata MF, Daulerio AJ, Covington MB, Nurnberg SA, Magolda RL, Trzaskos JM: Inhibition of MAP kinase kinase prevents cytokine and prostaglandin E2 production in lipopolysaccharide-stimulated monocytes. J Immunol 1998, 161:5681-5686.
39. Guha M, Mackman N: LPS induction of gene expression in human monocytes. Cell Signal 2001, 13:85-94.
40. Scherle PA, Jones EA, Favata MF, Daulerio AJ, Covington MB, Nurnberg SA, Magolda RL, Trzaskos JM: Inhibition of MAP kinase kinase prevents cytokine and prostaglandin E2 production in lipopolysaccharide-stimulated monocytes. J Immunol 1998, 161:5681-5686.